China Resources Double-Crane Pharmaceutical Co (SHSE:600062) ROCE %: 16.80% (As of Mar. 2026)


SHSE:600062 China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
90 GF Score
Price ¥16.43
GF Value ¥18.75
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China Resources Double-Crane Pharmaceutical Co ROCE %?

China Resources Double-Crane Pharmaceutical Co SHSE:600062 -0.90% 90 ROCE % is 16.80% as of Mar. 2026. GuruFocus rates SHSE:600062 with a GF Score™ of 90/100 and a GF Value™ of ¥18.75 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China Resources Double-Crane Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 16.80%.

China Resources Double-Crane Pharmaceutical Co  (SHSE:600062) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China Resources Double-Crane Pharmaceutical Co ROCE % Related Terms

China Resources Double-Crane Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for China Resources Double-Crane Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Double-Crane Pharmaceutical Co ROCE % Chart

China Resources Double-Crane Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.90 12.55 15.30 14.42 14.58

China Resources Double-Crane Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.55 17.32 11.99 8.62 16.80
SHSE:600062
90GF Score
China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Double-Crane Pharmaceutical Co ROCE % Calculation

China Resources Double-Crane Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1944.324/( ( (16685.996 - 4002.792) + (17009.183 - 3022.128) )/ 2 )
=1944.324/( (12683.204+13987.055)/ 2 )
=1944.324/13335.1295
=14.58 %

China Resources Double-Crane Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=2434.232/( ( (17009.183 - 3022.128) + (18007.138 - 3011.181) )/ 2 )
=2434.232/( ( 13987.055 + 14995.957 )/ 2 )
=2434.232/14491.506
=16.80 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.80% mean?
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a ROCE % of 16.80% as of Mar. 2026.
Is China Resources Double-Crane Pharmaceutical Co's ROCE % too high?
China Resources Double-Crane Pharmaceutical Co's current ROCE % is 16.80%. The Drug Manufacturers industry median ROCE % is 7.03. China Resources Double-Crane Pharmaceutical Co's value of 16.80% is 139% above this industry median. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's ROCE % compare to ZTS and UTHR?
China Resources Double-Crane Pharmaceutical Co's ROCE % of 16.80% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. China Resources Double-Crane Pharmaceutical Co's value of 16.80% is 139% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current ROCE % of 16.80% is 139% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current ROCE % is 16.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥16.43 — trading 12.4% below its estimated fair value. The current ROCE % is 16.80% and 139% above the Drug Manufacturers industry median of 7.03. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current ROCE % is 16.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75. GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600062:

  • ROCE %: 16.80%
  • GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
  • GF Score™: 90/100 with 4 warning signs
  • Industry Position: 139% above the Drug Manufacturers median

No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Double-Crane Pharmaceutical Co Business Description

Address No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score

Get the complete analysis for SHSE:600062

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.43
Price
¥18.75
GF Value